Notice NOT-EB-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-DC-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-096 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-037 from the NIH Guide for Grants and Contracts. NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the UM1 mechanism to fund Next Generation Chemistry Centers (NGC) for Fusion Oncoproteins that have independent research projects using innovative chemical biology technologies and chemoproteomic approaches to target fusion-driven cancers. The goal of these discovery efforts will be to identify and develop small molecules that effectively disrupt fusion oncoproteins through mechanisms including, but not limited to, inhibiting activities of individual fusion oncoproteins, blocking critical fusion protein interactions, interacting with coding and/or noncoding RNAs required for fusion protein oncogenesis, and selectively inducing fusion protein degradation or degradation of proteins representing critical fusion oncoprotein dependencies. Compounds envisaged to be derived from these efforts may be either at the level of chemical probes and tools to delineate underlying biology, advanced leads to support further optimization to a candidate, or potential drug candidates themselves. In addition to the research proposed in their applications, each NGC Center will be expected to participate in collaborative projects with the U01s and potentially other members of the fusion oncoprotein community. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on high-risk pediatric solid tumors and brain cancers are particularly encouraged. UM1 recipients will meet regularly with U01 grantees funded through the Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers FOA.

Funding Opportunity RFA-CA-23-036 from the NIH Guide for Grants and Contracts. NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the U01 mechanism to solicit applications focused on molecular mechanisms by which fusion oncoproteins drive pediatric cancers with the goals of better understanding the biology of these cancers and identifying potential drug targets or critical dependencies. Examples of relevant research activities include, but are not limited to, dissecting pathways by which these fusion oncoproteins cause cancer, characterizing the composition and structure of fusion oncoprotein complexes, and delineating the roles of ncRNAs and post-translational modifications in fusion oncoprotein function. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on pediatric solid tumors and brain tumors are particularly encouraged. U01 recipients will meet regularly with UM1 grantees funded through the Next Generation Chemistry Centers for Fusion Oncoproteins FOA.

Notice NOT-AI-23-044 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-22-512 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Cure Glomerulonephropathy (CureGN) Network by continuing to support the Participating Clinical Centers (PCCs). The CureGN Network is a multicenter observational cohort study of glomerular disease patients with the goal of improving care for all glomerular disease patients. The CureGN PCCs will continue to follow-up previously enrolled participants and enroll a limited number of new participants. The primary objective of the PCCs will be to optimize retention strategies, and methods for "remote" or "virtual" study participation; ensure complete and accurate data and biosample collection with a focus on clinical assessment of disease activity and outcomes. The DCC, under a separate NOFO, provides key leadership functions for this study in the areas of study organization, study design and implementation, and biosample management.

Notice NOT-AT-24-010 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-153 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-24-006 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the Molecular Atlas of Lung Development Program (LungMAP) Phase 3 Research Centers (RCs). The overall goal of LungMAP is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. RCs will be expected to obtain and analyze pediatric and adult lung tissues in order to generate high-resolution molecular profiling data of the diseased lung. RCs will perform integrated data analysis, explore mechanisms of disease pathogenesis, collaborate closely with other LungMAP teams and to disseminate this resource to the broader research community. Applicants are not required to have been funded in LungMAP Phase 2 (RFA-HL-19-020) in order to submit applications to this NOFO.

Funding Opportunity RFA-HL-24-007 from the NIH Guide for Grants and Contracts. The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.

Funding Opportunity RFA-HL-24-012 from the NIH Guide for Grants and Contracts. The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.

Funding Opportunity RFA-DK-22-513 from the NIH Guide for Grants and Contracts. This is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement award to the University of Michigan. The purpose of this Single SourceLimited Competition is to extend the Cure Glomerulonephropathy (CureGN) Network by continuing to support the Data Coordinating Center (DCC). The CureGN Network is a multicenter observational cohort study of glomerular disease patients with the goal of improving care for all glomerular disease patients. The DCC provides key leadership functions for this study in the areas of study organization, study design and implementation, overall management, data management and analysis, and biosample management. The CureGN Participating Clinical Centers (PCCs) will continue to follow-up previously enrolled participants under a separate NOFO.

Funding Opportunity RFA-EB-23-007 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

Funding Opportunity RFA-AT-24-005 from the NIH Guide for Grants and Contracts. This initiative will support a research resource for the continuation of a database of controlled trials of complementary and integrative health interventions, which are useful to those conducting systematic reviews. The research team will need to describe how to establish a database, maintain an existing database, or convert an existing database, as well as how it will be maintained and kept current during the award. The initiative will encourage increasing outreach, access, and availability of the database to a broader scientific community, the public and policy makers. The resource should update multiple reviews with current evidence and conduct new systematic reviews each year focusing on topics that are of priority to NCCIH (NCCIH Strategic Plan 2021-2025), particularly topics related to whole person research that include multi-component complementary and integrative health interventions. In the context of whole person health, topics should focus on the exploration of the fundamental science of interconnected systems, investigating multicomponent interventions or therapeutic systems, and/or examining the impact of these interventions on multisystem or multiorgan outcomes are of particular interest.

Notice NOT-NR-23-013 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-047 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-24-151 from the NIH Guide for Grants and Contracts. The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.

Funding Opportunity RFA-MH-24-150 from the NIH Guide for Grants and Contracts. To use a subset of drug development tools, which are being assessed in the AMP SCZ observational study, in a PoP trial with CHR individuals to determine the ability to detect a biological and/or clinical signal with the compound or compounds selected to use within a 12-16 week study period. The PoP trial will assess the performance of the PSYCHS, other clinical outcome measures, and biological measures. The compound or compounds that are selected for testing in the CHR Clinical Trial Network will affect a pathophysiologically relevant mechanism and have the potential to produce a detectable signal on biological and clinical outcome measures within a 12-16 week period of study.

Notice NOT-NS-23-092 from the NIH Guide for Grants and Contracts